PUT - SPRINTER OPEN END - NOVO-NORDISK B | Real-time Boerse Frankfurt Warrants 14:01:50 2024-06-24 EDT | ||
| 0.37 EUR | 0.00% |
|
| Current month | -69.92% | ||
| 1 month | -62.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-24 | 0.37 | 0.00% |
| 24-06-20 | 0.37 | -22.92% |
| 24-06-19 | 0.48 | -11.11% |
| 24-06-18 | 0.54 | +28.57% |
| 24-06-17 | 0.42 | +44.83% |
Real-time Boerse Frankfurt Warrants
Last update June 24, 2024 at 02:01 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM97LU |
| ISIN | DE000VM97LU7 |
| Date issued | 2024-02-12 |
| Strike | 1,012 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.48 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.71 € |
|---|---|
| Lowest since issue | 0.28 € |
| Spread | 0.29 € |
| Spread % | 53.70% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
988.4
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.48%
- Stock Market
- Certificates
- Certificat
